title: Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis.
abstract: Antibiotics are often used in the clinic to treat bacterial infections, but the effects of these drugs on microbiota composition and on intestinal immunity are poorly understood. Citrobacter rodentium was used as a model enteric pathogen to investigate the effect of microbial perturbation on intestinal barriers and susceptibility to colitis. Streptomycin and metronidazole were used to induce alterations in the composition of the microbiota prior to infection with C. rodentium. Metronidazole pretreatment increased susceptibility to C. rodentium-induced colitis over that of untreated and streptomycin-pretreated mice, 6 days postinfection. Both antibiotic treatments altered microbial composition, without affecting total numbers, but metronidazole treatment resulted in a more dramatic change, including a reduced population of Porphyromonadaceae and increased numbers of lactobacilli. Disruption of the microbiota with metronidazole, but not streptomycin treatment, resulted in an increased inflammatory tone of the intestine characterized by increased bacterial stimulation of the epithelium, altered goblet cell function, and thinning of the inner mucus layer, suggesting a weakened mucosal barrier. This reduction in mucus thickness correlates with increased attachment of C. rodentium to the intestinal epithelium, contributing to the exacerbated severity of C. rodentium-induced colitis in metronidazole-pretreated mice. These results suggest that antibiotic perturbation of the microbiota can disrupt intestinal homeostasis and the integrity of intestinal defenses, which protect against invading pathogens and intestinal inflammation.
authors.affiliation: Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Wlodarska
authors.forename: B
authors.initials: B
authors.lastname: Willing
authors.forename: K M
authors.initials: KM
authors.lastname: Keeney
authors.forename: A
authors.initials: A
authors.lastname: Menendez
authors.forename: K S
authors.initials: KS
authors.lastname: Bergstrom
authors.forename: N
authors.initials: N
authors.lastname: Gill
authors.forename: S L
authors.initials: SL
authors.lastname: Russell
authors.forename: B A
authors.initials: BA
authors.lastname: Vallance
authors.forename: B B
authors.initials: BB
authors.lastname: Finlay
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D002469:Cell Separation; D044082:Citrobacter rodentium / Q000276:immunology; D003092:Colitis / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D004756:Enterobacteriaceae Infections / Q000276:immunology* / Q000382:microbiology* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D018928:Immunity, Mucosal / Q000187:drug effects; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000382:microbiology* / Q000473:pathology; D008795:Metronidazole / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013307:Streptomycin / Q000633:toxicity
chemical_list: D000900:Anti-Bacterial Agents; D008795:Metronidazole; D013307:Streptomycin